Abstract 504
Background
Cancer is one of the leading causes of death worldwide. Most deaths from cancer occurs in low- and middle- income countries, which might be explained by the delayed presentation of the cancer patient. Inadequate public awareness of signs and symptoms of cancer and its risk factors is one of the factors related to this. Our study aimed to assess the level of public awareness of cancer prevalence, symptoms and signs as well as risk factors in Gaza.
Methods
This is a cross-sectional study conducted from September to October 2017 in the Gaza-Strip, Palestine. Stratified sampling was used to recruit three major hospitals and ten high schools. A previously pilot-tested, Arabic version of the Cancer Awareness Measure (CAM) questionnaire, which is a validated standardized questionnaire to measure public cancer awareness, was used. It involves four sections: sociodemographics, awareness of cancer prevalence, cancer symptoms and alarming signs, and cancer risk factors. Adults (aged ≥18 years) visiting or admitted to any of the three hospitals, and adolescents (aged 15-17 years) in any of the ten schools were recruited for face-to-face interviews. Patients and visitors to oncology departments were ineligible. Informed consent and ethical approval were obtained. Data were analyzed with SPSS (version 23).
Results
A total of 2886 participants completed the CAM questionnaire (of 3033 approached; response rate was 95.2%). 1483 (51.4%) were women, and 1457 (50.5%) were adolescents. Overall, 2220 (76.9%) identified breast cancer as the most common cancer among women in the Gaza-Strip but only 196 (6.7%) identified colorectal cancer as the most common cancer among males. 1885 (65.2%) thought that the chance of getting cancer is not related to age. A lump was the most commonly recognized cancer symptom (n = 2227, 77.1%) while change of bowel habit was the least (n = 670, 23.2%). Smoking was the most frequently recognized cancer risk factor (n = 2215, 76.7%) and eating less than 5 portions of fruit and vegetables a day was the least (n = 514, 17.8%). The overall mean score for awareness of cancer symptoms is 3.5 ± 1.7 out of 8 and that of risk factors is 7.9 ± 3.1 out of 16.
Conclusions
Level of cancer awareness in Gaza is low. Educational interventions to raise public awareness of cancer are urgently required.
Clinical trial identification
Legal entity responsible for the study
Palestinian Ministry of Health.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1147 - Major determinants of delayed access to innovative medicines for metastatic melanoma: the results of Melanoma World Society and European Association of Dermato-oncology survey
Presenter: Lidija Kandolf Sekulovic
Session: Poster Discussion session - Public health policy
Resources:
Abstract
4876 - Variation in Oncology Drug Approvals in Canada, the United States and Europe
Presenter: Omar Khan
Session: Poster Discussion session - Public health policy
Resources:
Abstract
Poster Discussion session - Public health policy - Invited Discussant 1560PD and 1561PD
Presenter: Carin Uyl-de Groot
Session: Poster Discussion session - Public health policy
Resources:
Slides
Webcast
2915 - Magnitude of Clinical Benefit of Cancer Drugs Approved Based on Single-Arm Trials (SAT) by the US Food and Drug Administration (FDA)
Presenter: Consolacion Molto Valiente
Session: Poster Discussion session - Public health policy
Resources:
Abstract
4334 - Magnitude of Clinical Benefit in Trials Supporting US Food and Drug Administration (FDA) Accelerated Approval (AA) and European Medicines Agency (EMA) Conditional Marketing Authorisation (CMA) and Subsequent Trials Supporting Conversion to Full Approval
Presenter: Maria Borrell Puy
Session: Poster Discussion session - Public health policy
Resources:
Abstract
4001 - Magnitude of Clinical Benefit of Trials Supporting US Food and Drug Administration (FDA) Approval of Breakthrough and Non-breakthrough Drugs
Presenter: Consolacion Molto Valiente
Session: Poster Discussion session - Public health policy
Resources:
Abstract
4365 - Time to access to novel anticancer therapies in Slovenia in view of the ESMO-MCBS scores
Presenter: Urska Janzic
Session: Poster Discussion session - Public health policy
Resources:
Abstract
Poster Discussion session - Public health policy - Invited Discussant 1563PD, 1564PD and 1565PD
Presenter: Fredericus Eskens
Session: Poster Discussion session - Public health policy
Resources:
Slides
Webcast
4536 - Cascade BRCA Germline Mutation (BGM) Testing of women with Breast (BC) or Epithelial Ovarian Cancer( EOC) and their families with subsequent Risk Reducing Surgery(RRS): A Canadian Economics Model
Presenter: paul Hoskins
Session: Poster Discussion session - Public health policy
Resources:
Abstract
1746 - Genetic testing of BRCA mutations in breast cancer in six European countries: Barriers and opportunities
Presenter: Maia Thrift-Perry
Session: Poster Discussion session - Public health policy
Resources:
Abstract